Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy
C. Lukas, B. Bellenberg, H.K. Hahn, J. Rexilius, R. Drescher, K. Hellwig, O. Köster, S. Schimrigk, Therapeutic Advances in Neurological Disorders 2 (2009) 349–355.
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Artikel
| Veröffentlicht
| Englisch
Autor*in
Lukas, Carsten;
Bellenberg, Barbara;
Hahn, Horst K.;
Rexilius, Jan
;
Drescher, Robert;
Hellwig, Kerstin;
Köster, Odo;
Schimrigk, Sebastian
;
Drescher, Robert;
Hellwig, Kerstin;
Köster, Odo;
Schimrigk, SebastianErscheinungsjahr
Zeitschriftentitel
Therapeutic Advances in Neurological Disorders
Band
2
Zeitschriftennummer
6
Seite
349-355
ISSN
eISSN
FH-PUB-ID
Zitieren
Lukas, Carsten ; Bellenberg, Barbara ; Hahn, Horst K. ; Rexilius, Jan ; Drescher, Robert ; Hellwig, Kerstin ; Köster, Odo ; Schimrigk, Sebastian: Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. In: Therapeutic Advances in Neurological Disorders Bd. 2, SAGE Publications (2009), Nr. 6, S. 349–355
Lukas C, Bellenberg B, Hahn HK, et al. Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. Therapeutic Advances in Neurological Disorders. 2009;2(6):349-355. doi:10.1177/1756285609343480
Lukas, C., Bellenberg, B., Hahn, H. K., Rexilius, J., Drescher, R., Hellwig, K., … Schimrigk, S. (2009). Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. Therapeutic Advances in Neurological Disorders, 2(6), 349–355. https://doi.org/10.1177/1756285609343480
@article{Lukas_Bellenberg_Hahn_Rexilius_Drescher_Hellwig_Köster_Schimrigk_2009, title={Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy}, volume={2}, DOI={10.1177/1756285609343480}, number={6}, journal={Therapeutic Advances in Neurological Disorders}, publisher={SAGE Publications}, author={Lukas, Carsten and Bellenberg, Barbara and Hahn, Horst K. and Rexilius, Jan and Drescher, Robert and Hellwig, Kerstin and Köster, Odo and Schimrigk, Sebastian}, year={2009}, pages={349–355} }
Lukas, Carsten, Barbara Bellenberg, Horst K. Hahn, Jan Rexilius, Robert Drescher, Kerstin Hellwig, Odo Köster, and Sebastian Schimrigk. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy.” Therapeutic Advances in Neurological Disorders 2, no. 6 (2009): 349–55. https://doi.org/10.1177/1756285609343480.
C. Lukas et al., “Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy,” Therapeutic Advances in Neurological Disorders, vol. 2, no. 6, pp. 349–355, 2009.
Lukas, Carsten, et al. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy.” Therapeutic Advances in Neurological Disorders, vol. 2, no. 6, SAGE Publications, 2009, pp. 349–55, doi:10.1177/1756285609343480.
Google Scholar